Physician profile
David W Snyder
NPI 1184620379
$1,838.32
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $927 · 2020: $194 · 2021: $684 · 2022: $33.11.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $292.88 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $280.82 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $244.87 | 2019-2021 | |
| Pfizer INC. | $149.42 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $145.54 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $143.50 | 2019-2021 | |
| Amarin Pharma, INC. | $136.25 | 2019-2021 | |
| Amgen INC. | $132.47 | 2019-2021 | |
| Esperion Therapeutics, INC. | $63.39 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.65 | 2019 | |
| Gilead Sciences, INC. | $40.93 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $39.98 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $37.61 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $33.72 | 2021-2022 | |
| Actelion Pharmaceuticals US, INC. | $18.60 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Terumo Medical Corporation | $17.78 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $13.91 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Snyder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.